Monica Piras

Monica Piras

Auto-generated profile, based on publicly available information

Monica Piras

Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, U.K.

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2018 in Nature
Verified
Journal Article
Open access
PDF file
MSMark H. T. Stappers
Mark H. T. Stappers
ACAlexandra E. Clark
Alexandra E. Clark
VAVishukumar AIMANIANDA
Vishukumar AIMANIANDA
SBStefan Bidula
Stefan Bidula
DRDelyth M. Reid
Delyth M. Reid
GBGordon D. Brown
Gordon D. Brown
Resistance to infection is critically dependent on the ability of pattern recognition receptors to recognize microbial invasion and induce protective immune responses. One such family of receptors are the C-type lectins, which are central to antifungal immunity1. These receptors activate key effector mechanisms upon recognition of conserved fungal cell-wall carbohydrates. However, several other immunologically active fungal ligands have been described; these include melanin2,3, for which the mechanism of recognition is hitherto undefined. Here we identify a C-type lectin receptor, melanin-sensing C-type lectin receptor (MelLec), that has an essential role in antifungal immunity through recognition of the naphthalene-diol unit of 1,8-dihydroxynaphthalene (DHN)-melanin. MelLec recognizes melanin in conidial spores of Aspergillus fumigatus as well as in other DHN-melanized fungi. MelLec is ubiquitously expressed by CD31+ endothelial cells in mice, and is also expressed by a sub-population of these cells that co-express epithelial cell adhesion molecule and are detected only in the lung and the liver. In mouse models, MelLec was required for protection against disseminated infection with A. fumigatus. In humans, MelLec is also expressed by myeloid cells, and we identified a single nucleotide polymorphism of this receptor that negatively affected myeloid inflammatory responses and significantly increased the susceptibility of stem-cell transplant recipients to disseminated Aspergillus infections. MelLec therefore recognizes an immunologically active component commonly found on fungi and has an essential role in protective antifungal immunity in both mice and humans.

15 May 2013 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
SDSergio Dall'Angelo
Sergio Dall'Angelo
QZQingzhi Zhang
Qingzhi Zhang
IFIan N. Fleming
Ian N. Fleming
MPMonica Piras
Monica Piras
LSLutz F. Schweiger
Lutz F. Schweiger
MZMatteo Zanda
Matteo Zanda
The utility of 5-fluoro-5-deoxyribose (FDR) as an efficient bioconjugation agent for radiolabelling of the RGD peptides c(RGDfK) and c(RGDfC) is demonstrated. The bioconjugation is significantly superior to that achieved with 2-fluoro-2-deoxyglucose (FDG) and benefits from the location of the fluorine at C-5, and that ribose is a 5-membered ring sugar rather than a 6-membered ring. Both features favour ring opening to the aldehydic form of the sugar to promote smooth oxime ligation with aminooxy ether functionalised peptides. [18F]FDR was prepared in this study by synthesis from fluoride-18 using an automated synthesis protocol adapting that used routinely for [18F]FDG. c(RGDfK) was functionalised with an aminooxyacetyl group (Aoa) via its lysine terminus, while c(RGDfC) was functionalised with an aminooxyhexylmaleimide (Ahm) through a cysteine–maleimide conjugation. Bioconjugation of [18F]FDR to c(RGDfC)-Ahm proved to be more efficient than c(RGDfK)-Aoa (92% versus 65%). The unlabelled (19F) bioconjugates c(RGDfK)-Aoa-FDR and c(RGDfC)-Ahm-FDR were prepared and their in vitro affinity to purified integrin αvβ3 was determined. c(RGDfK)-Aoa-FDR showed the greater affinity. Purified “hot” bioconjugates c(RGDfK)-Aoa-[18F]FDR and c(RGDfC)-Ahm-[18F]FDR were assayed by incubation with MCF7, LNCaP and PC3 cell lines. In both cases the conjugated RGD peptides showed selectivity for PC3 cells, which express αvβ3 integrin, with the c(RGDfK)-Aoa-[18F]FDR demonstrating better binding, consistent with its higher in vitro affinity. The study demonstrates that [18F]FDR is an efficient bioconjugation ligand for RGD bioactive peptides.

2 May 2016 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
AGAlessandra Graziadio
Alessandra Graziadio
MZMatteo Zanda
Matteo Zanda
SFSimona Frau
Simona Frau
IFIan N. Fleming
Ian N. Fleming
MMManuele Musolino
Manuele Musolino
MPMonica Piras
Monica Piras

17 January 2019 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
PLPhillip T. Lowe
Phillip T. Lowe
SDSergio Dall'Angelo
Sergio Dall'Angelo
IFIan N. Fleming
Ian N. Fleming
MPMonica Piras
Monica Piras
MZMatteo Zanda
Matteo Zanda
DODavid O'HAgan
David O'HAgan
FDA-PEG-GUL was enzymatically synthesised using the fluorinase in 18 F-radiolabelled form and shown to efficiently bind the prostate-specific antigen (PSMA) which is upregulated in prostate cancer cells.

4 January 2011 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
Roberta BerniniRoberta Bernini
Roberta Bernini
FCFernanda Crisante
Fernanda Crisante
PGPatrizia Gentili
Patrizia Gentili
FMFabio Morana
Fabio Morana
MPMarco Pierini
Marco Pierini
MPMonica Piras
Monica Piras

10 July 2017 in Molecular Imaging and Biology
Verified
Journal Article
Open access
PDF file
AAAlexandra Andriu
Alexandra Andriu
JCJulie Crockett
Julie Crockett
SDSergio Dall’aNgelo
Sergio Dall’aNgelo
MPMonica Piras
Monica Piras
MZMatteo Zanda
Matteo Zanda
IFIan N. Fleming
Ian N. Fleming
Purpose Molecular imaging of αvβ3 integrin has exhibited real potential to guide the appropriate use of anti-angiogenic therapies. However, an incomplete understanding of the factors that influence binding of αvβ3 integrin-specific radiotracers currently limits their use for assessing response to therapy in cancer patients. This study identifies two fundamental factors that modulate uptake of these radiotracers. Procedures Experiments were performed in prostate cancer (PC3) and glioblastoma (U87MG) cells, which differentially express αvβ3 integrin. αvβ3 integrin-specific radiotracers were used to investigate the effect of manipulating αvβ3 integrin expression or activation in cellular binding assays. β3 integrin and αvβ3 integrin expression were measured by western blotting and flow cytometry, respectively. The effect of select pharmacological inhibitors on αvβ3 integrin activation and expression was also determined. Results Radiotracer binding was proportional to αvβ3 integrin expression when it was decreased (β3 knock-down cells) or increased, either using pharmacological inhibitors of cell signalling or by culturing cells for different times. Studies with both small molecule and arginine–glycine–aspartic acid (RGD)-based radiotracers revealed increased radiotracer binding after activation of αvβ3 integrin with Mn2+ or talin head domain. Moreover, inhibition of fundamental signalling pathways (mitogen-activated protein kinase kinase (MEK), Src and VEGFR2) decreased radiotracer binding, reflecting reduced αvβ3 integrin activity. Conclusion Binding of small molecule ligands and radiolabelled RGD peptides is modulated by expression and activation status of αvβ3 integrin. αvβ3 integrin-specific radiotracers can provide otherwise inaccessible information of the effect of signalling pathways on αvβ3 integrin. This has significant implications for assessing response to anti-angiogenic therapies in clinical studies.